Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Next ScienceNXSCF Days Payable is 263.31 as of Jun. 2025, which is 157% above its 10-year median of 102.45. The stock has 7 warning signs investors should review.
The historical data trend for Next Science's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NXSCF vs GCAN, PTPI, GRPS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Next Science Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Next Science's Days Payable distribution charts can be found below:
* The bar in red indicates where Next Science's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Next Science's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Next Science (NXSCF) has a Days Payable of 263.31 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Next Science and its competitors. This is 157% above median its historical median of 102.45. Over the past decade, Next Science's Days Payable has ranged from 73.23 to 589.90.
Is Next Science's Days Payable too high?
Next Science's current Days Payable of 263.31 is 157% above median its 10-year median of 102.45. Over the past 10 years, this metric has ranged from a low of 73.23 to a high of 589.90. The Drug Manufacturers industry median Days Payable is 88.75. Next Science's value of 263.31 is 196.7% above this industry median.
How does Next Science's Days Payable compare to GCAN and PTPI?
Next Science's Days Payable of 263.31 can be compared against companies in the Drug Manufacturers industry. The industry median Days Payable is 88.75. Next Science's value of 263.31 is 196.7% above this benchmark. Historically, Next Science's own Days Payable has ranged from 73.23 to 589.90 over the past decade. While the company's 10-year median is 102.45 vs. the industry median of 88.75, Next Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.75, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Next Science's current Days Payable of 263.31 is 196.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Next Science and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Next Science's current Days Payable is 263.31, which is 157% above median its own 10-year median of 102.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (NXSCF) has a current Days Payable of 263.31. The stock's GF Value™ is $0.26, compared to a current price of $0.00 — trading 99.6% below its estimated fair value. The current Days Payable is 263.31, which is 157% above median its 10-year median of 102.45 and 196.7% above the Drug Manufacturers industry median of 88.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Next Science (NXSCF), the current Days Payable is 263.31 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXSCF has been successfully added to your 
